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ORIGINAL RESEARCH

Early Invasive Strategy and In-Hospital Survival Among Diabetics With
Non-ST-Elevation Acute Coronary Syndromes: A Contemporary
National Insight
Ahmed N. Mahmoud, MD;* Islam Y. Elgendy, MD;* Hend Mansoor, PharmD, MS; Xuerong Wen, PhD, MPH, MS; Mohammad K. Mojadidi,
MD; Anthony A. Bavry, MD, MPH; R. David Anderson, MD, MS

Background-—There are limited data on the merits of an early invasive strategy in diabetics with non-ST-elevation acute coronary
syndrome, with unclear inﬂuence of this strategy on survival. The aim of this study was to evaluate the in-hospital survival of
diabetics with non-ST-elevation acute coronary syndrome treated with an early invasive strategy compared with an initial
conservative strategy.
Methods and Results-—The National Inpatient Sample database, years 2012–2013, was queried for diabetics with a primary
diagnosis of non-ST-elevation acute coronary syndrome deﬁned as either non-ST-elevation myocardial infarction or unstable angina
(unstable angina). An early invasive strategy was deﬁned as coronary angiographyrevascularization within 48 hours of admission.
Propensity scores were used to assemble a cohort managed with either an early invasive or initial conservative strategy balanced
on >50 baseline characteristics and hospital presentations. Incidence of in-hospital mortality was compared in both groups. In a
cohort of 363 500 diabetics with non-ST-elevation acute coronary syndrome, 164 740 (45.3%) were treated with an early invasive
strategy. Propensity scoring matched 21 681 diabetics in both arms. Incidence of in-hospital mortality was lower with an early
invasive strategy in both the unadjusted (2.0% vs 4.8%; odds ratio [OR], 0.41; 95% CI, 0.39–0.42; P<0.0001) and propensitymatched models (2.2% vs 3.8%; OR, 0.57; 95% CI, 0.50–0.63; P<0.0001). The beneﬁt was observed across various subgroups,
except for patients with unstable angina (Pinteraction=0.02).
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Conclusions-—An early invasive strategy may be associated with a lower incidence of in-hospital mortality in patients with
diabetes. The beneﬁt of this strategy appears to be superior in patients presenting with non-ST-elevation myocardial infarction
compared with unstable angina. ( J Am Heart Assoc. 2017;6:e005369. DOI: 10.1161/JAHA.116.005369)
Key Words: acute coronary syndrome • early invasive strategy • mortality • propensity score analysis

D

iabetes mellitus (DM) is a rapidly growing global health
burden. In 2014, the prevalence of DM was estimated to
be 422 million worldwide, doubling in frequency since 1980.1
In the United States, the prevalence of DM increased
dramatically from 3.5% in 1990 to 8.3% in 2012.2 DM is a
predominant risk factor for atherosclerotic coronary artery
disease (CAD) and acute myocardial infarction (MI).3,4
Diabetics have a higher incidence of multivessel CAD,

accelerated atherosclerosis, atherosclerotic plaque rupture,
and increased platelet activity, all of which increase the
incidence of acute MI compared to nondiabetics.4 Additionally, DM is independently associated with a higher incidence
of early and late mortality following a non-ST-elevation acute
coronary syndrome (NSTE-ACS).5,6
There is currently a paucity of data on the beneﬁt of an
early invasive strategy in diabetic patients with NSTE-ACS,
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The National Inpatient Sample (NIS) database (years 2012 and
2013) was used to collect data for the current study. Years
2012 and 2013 were chosen because those were the most
recent NIS database releases at the time this study was
conducted and thus would most closely reﬂect contemporary
management of NSTE-ACS. In 2012, the NIS was redesigned to
include a random sample of patient discharges from all
hospitals, rather than a random sample of hospitals retaining
their discharges, which resulted in more-precise national
estimates. The NIS is the largest all-payer database in the
United States available for public use and sponsored by the
Agency for Healthcare Research and Quality (AHRQ) as a part of
the Healthcare Cost and Utilization Project.13 It represents a
20% stratiﬁed sample of all discharges from the US community
hospitals. Each individual patient hospitalization is de-identiﬁed
and maintained as a speciﬁc entry. Data available in the NIS
include 1 primary and 24 secondary diagnoses, 25 procedure
diagnoses (in International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation [ICD-9-CM] coding format),
patient demographic characteristics (eg, sex, age, race, and
median household income), hospital characteristics (eg, ownership), expected payment source, total hospital charges,
discharge status, length of hospital stay, as well as, severity
and comorbidity measures. Discharge weights are also available for each patient’s record, which could be used in national
weighted estimates generation. This study was deemed to be
exempt from the Institutional Review Board (IRB) because of
the public nature of the NIS database, with the absence of any
personal identifying information.
DOI: 10.1161/JAHA.116.005369

Validation and Data Control
The NIS performs annual data quality assessments, to ensure
the internal validly of its data. It had been previously
compared with alternative databases, such as American
Hospital Association Annual Survey Database, the National
Hospital Discharge Survey from the National Center for Health
Statistics, and the Med-PAR inpatient database from Centers
for Medicare and Medicaid Services, with comparable
estimates to all of the previously stated databases.14

Patient Population
All patients with a primary diagnosis code of non-ST-elevation
myocardial infarction (NSTEMI) (ICD-9-CM code of 410.7x) or
unstable angina (UA; ICD-CM 9 code of 411.1) and secondary
diagnosis of diabetes mellitus (according to the Elixhauser
comorbidity software deﬁned by the AHRQ) were included.15
The analysis was limited to patients with the primary diagnosis
of NSTE-ACS as it is usually considered the main reason for
admission in the NIS database. This would allow the exclusion
of patients with type 2 NSTEMI secondary to other concomitant
diseases. An early invasive strategy group was deﬁned as
coronary angiography (ICD-9-CM codes of 88.55, 37.22, or
37.23) with or without revascularization, that is, percutaneous
coronary intervention (PCI; ICD-9-CM codes of 00.66, 36.01,
36.02, 36.05, 36.06, and 36.07) or coronary artery bypass
grafting (CABG; ICD-9-CM code 36.1x) with procedure time
being within 48 hours of admission (ie, day 0 or 1). The
remaining patients were deﬁned as an initial conservative
strategy group. This deﬁnition of an early invasive strategy in
NSTE-ACS has previously been used for other studies utilizing
data from the NIS database.16,17

Study Outcomes
The main outcome of this study was in-hospital mortality,
referred to in the NIS database as the “DIED” variable. The
main outcome was compared in both the early invasive and
initial conservative strategy groups after adjusting for multiple
patient and hospital characteristics. Other outcomes of
interest were length of hospital stay, referred in the NIS
database as “LOS” variable and total hospital charges,
referenced as the “TOTCHG” variable. The total hospital
charges represent the total amount billed by the hospital for
service rather than the actual payment received.

Patients and Hospital Characteristics
Data variables collected were patients’ demographics, including age, sex, race, median household income by ZIP code,
weekend versus weekday admission, and primary expected
payer (Medicare, Medicaid, Private insurance, Uninsured, or
Journal of the American Heart Association
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given the limited number of diabetic patients enrolled in most
randomized, clinical trials.7 Multiple observational studies and
meta-analyses of randomized trials demonstrate the beneﬁt of
an early invasive strategy in management of diabetic NSTEACS patients, mainly through reduction of composite clinical
event rates and MI.8,9 As a direct consequence, the American
College of Cardiology Foundation/American Heart Association (ACCF/AHA) Task Force recommends a routine invasive
strategy (within 72 hours of hospitalization) for diabetics
presenting with NSTE-ACS.10 However, evidence from real-life
registry data indicates that diabetics are less frequently
offered acute reperfusion therapy or acute revascularization
compared to nondiabetics.6,11,12
To date, there is insufﬁcient evidence to support a survival
beneﬁt of an early invasive strategy in diabetic patients with
NSTE-ACS. The aim of this study is to evaluate the effect of an
early invasive strategy in NSTE-ACS diabetic patients, with
emphasis on survival, length of hospital stay, and cost.
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Variable

ICD-9-CM Code

Acute ischemic stroke

433.01, 433.11, 433.21, 433.31,
433.81433.91, 434.01, 434.11,
434.91, 435.x, 436

Intracranial hemorrhage

430, 431, 432.x

Gastrointestinal bleeding

153

Cardiogenic shock

785.51

Family history of CAD

V17.3

Past MI

412

Past PCI

V45.82

Past CABG

V45.81

Past stroke/TIA

V12.54

CAD

414.00, 414.01, 414.02, 414.03, 414.04,
414.05, 414.06, 414.07

Carotid artery disease

433.10

Smoking history

V15.82, 305.1

Dyslipidemia

53

Atrial fibrillation

427.31

Dementia

290.xx, 294.1x, 294.2x, 294.8,
331.0–331.12, 331.82, 797

Downloaded from http://ahajournals.org by on February 27, 2019

CABG indicates coronary artery bypass grafting; CAD, coronary artery disease; MI,
myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic
attack.
*Other variables not reported in the table were collected using Elixhauser Comorbidity
Software.15

Other) and the Elixhauser list of comorbidities. Other relevant
diagnoses were also extracted by their corresponding ICD-9CM codes, including acute ischemic stroke, intracranial
hemorrhage, gastrointestinal bleeding, cardiogenic shock,
family history of coronary artery disease (CAD), history of
past MI, past PCI or CABG, past stroke or transient ischemic
attack (TIA), CAD, carotid artery disease, smoking, dyslipidemia, atrial ﬁbrillation, and dementia. Hospital characteristics, such as bed size (small, medium, and large), urban
location, and teaching status, were also collected.18 A full list
of ICD-9-CM codes for all variables collected in the current
study is supplied in Table 1.

Statistical Analysis
Weighted national estimates were calculated using the
discharge weights supplied by the NIS. Frequencies and
percentages were used for estimation of categorical patient
and hospital characteristics and means with SD or medians,
with 25th to 75th percentile ranges, for continuous ones.
Categorical variables were compared by Pearson’s chi-square
DOI: 10.1161/JAHA.116.005369

test, and an independent-sample Student t test was used for
means comparison in both groups. Medians were compared
using Mood’s median test. A multivariable logistic regression
model was constructed using all previously stated patient and
hospital characteristics as independent variables, with early
invasive strategy being the dependent variable. The resultant
individually matched probability score was then used for
propensity score matching of 2 similar groups (an early
invasive strategy vs initial conservative strategy) with 1:1 ratio
and match tolerance of 0.01. A clinically signiﬁcant difference
between both groups was considered present if the absolute
difference in frequency or means was >5% postmatching. The
propensity-matched cohort of patients was then used to
compare the incidence of different outcomes of interest. The
odds ratio (OR) of in-hospital mortality was calculated in the
propensity-matched data using a binary conditional logistic
regression model.
A subgroup analysis was conducted comparing the OR of
in-hospital mortality according to the use of an early invasive
strategy across various predeﬁned subsets, including
NSTEMI versus UA, history of congestive heart failure
(CHF), presence of cardiogenic shock, males versus females,
and past history of MI, CAD, or revascularization (PCI or
CABG). A secondary propensity adjusted multivariable logistic regression analysis was also calculated for in-hospital
mortality with all previously stated variables along with the
use of early invasive strategy and the propensity score as
independent variables. The regression was performed by a
backward step-wise approach with a cut-off level of 0.05 for
entry and 0.1 for removal, followed by calculation of an
adjusted OR for in-hospital mortality.
To take into account the possibility of an immortality
time bias, a sensitivity analysis was conducted after
exclusion of NSTE-ACS patients who had a length of hospital
stay less than 48 hours (ie, day 0 and 1) in the propensitymatched cohort. Immortal time bias refers to a period of
follow-up during which, by design, the study outcome cannot
occur.19 Limiting the analysis to patients, who had a length
of hospital stay more than 48 hours, was an indirect method
of analyzing patients who survived for at least 48 hours, as
the time of death was not a reported variable in the NIS
database.
Finally, another propensity score analysis was conducted
using a tighter match tolerance of 10e 5 to conﬁrm the
ﬁndings of the primary analysis, because a statistically
signiﬁcant difference in the frequency of some categorical
variables was detected in the primary analysis. All statistical
analyses were performed using IBM SPSS Statistics software
(version 23.0; IBM Corp., Armonk, NY) with 2-sided P value of
<0.05 for statistical signiﬁcance assessment for all analyses
and OR with 95% CI as a measure of effect size reported by
logistic regression.
Journal of the American Heart Association
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Table 1. International Classiﬁcation of Diseases, Ninth
Edition, Clinical Modiﬁcation (ICD-9-CM) Codes of the
Variables Included in the Propensity Score Matching*
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Baseline Characteristics
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We identiﬁed 363 500 diabetic patients who were admitted
in the United States with a primary diagnosis of NSTE-ACS
(mean age, 68.112.6 years; 42.9% female; 64.5% being
white; 65.5% covered by Medicare) during the years 2012–
2013. Most of the patients were hypertensive (82.8%) and
had a past history of CAD (77.9%). A total of 229 435
patients (63.1%) underwent an invasive strategy (early or
delayed) during their admission (coronary angiography, PCI,
or CABG). Of the total patient population, 164 740 patients
(45.3%) had an early invasive strategy performed during
their hospital stay. Total incidence of in-hospital mortality
was 12 925 patients (3.9%). Patient and hospital characteristics of the included patients are summarized in
Table 2.
Compared with an initial conservative strategy, patients
undergoing an early invasive strategy were younger (65.2
[SD=11.8] vs 70.6 [SD=12.8] years; P<0.0001), less frequently female (38.9% vs 46.3%; P<0.0001), and had fewer
comorbidities (Table 2). The use of an early invasive strategy
was more common in large-bed-size hospitals and in urban
teaching hospitals (Table 2). Patients carrying a diagnosis of
UA were less likely to undergo an early invasive strategy
compared to those with NSTEMI (21.3% vs 45.3%; P<0.0001).
The frequency of revascularization was higher in the early
invasive strategy group by both PCI (96.9% vs 30.1%;
P<0.0001) and CABG (15.6% vs 5.9%; P<0.0001) (Table 2).
Nonetheless, all patients in the initial conservative strategy
group who had a coronary angiography performed had a
revascularization procedure (i.e. PCI and/or CABG) as well.
Propensity score matching yielded 21 681 patients in both
groups with a similar distribution of patient and hospital
characteristics between the 2 groups of interest, except for a
few categorical variables such as expected primary payer
(P<0.0001), race (P<0.0001), median household income
(P=0.02), and hospital location (P<0.0001). However, all
variables had absolute frequency differences less than 5%
and thus deemed clinically insigniﬁcant (Table 2). To conﬁrm
our results, a secondary propensity score analysis was
constructed with a tighter match tolerance of 10e 5 that
yielded 12 363 patients in the early invasive strategy group and
12 367 in the initial conservative approach group, matched in
all the formerly stated categorical variables (Table S1).

In-Hospital Mortality
The incidence of in-hospital mortality was lower with an early
invasive compared with an initial conservative strategy in the
unadjusted cohort (2.0% vs 4.8%; OR, 0.41; 95% CI, 0.39–
0.42; P<0.0001). This beneﬁt was maintained in the

DOI: 10.1161/JAHA.116.005369

propensity-matched cohort (2.2% vs 3.8%; OR, 0.57; 95% CI,
0.50–0.63; P<0.0001) and in the propensity-adjusted multivariable logistic regression analysis (OR, 0.54; 95% CI, 0.52–
0.57; P<0.0001; Figure 1). The incidence of in-hospital
mortality also was lower with an early invasive strategy in
the secondary post-hoc analysis using a tighter match
tolerance (2.5% vs 3.7%; OR, 0.65; 95% CI, 0.56–0.75;
P<0.0001) and in the sensitivity analysis after excluding the
patients with length of hospital stay less than 48 hours in the
propensity-matched cohort (2.1 vs 3.3; OR, 0.63; 95% CI,
0.56–0.72; P<0.0001).
On subgroup analysis, the beneﬁt of an early invasive
strategy was demonstrated among a wide range of prespeciﬁed subgroups except in patients with UA, where there was
no apparent evidence of survival beneﬁt with an early invasive
strategy (0.5% vs 0.1%; OR, 7.86; 95% CI, 0.82–75.72;
P=0.07), with evidence of heterogeneity when compared to
NSTEMI patients (Pinteraction=0.02; Figure 2).

Other Outcomes
An early invasive strategy was associated with a shorter
length of hospital stay compared with an initial conservative
strategy with a median of 3 (2–7) versus 4 days (2–7),
respectively (P<0.0001), and higher total hospital charges
with a median of 66 042 US dollars ($40315–112895) versus
39 265$ (19 193–77 832$), respectively (P<0.0001;
Figure 1).

Discussion
In the current propensity-matched analysis of contemporary
real-life data, an early invasive strategy was associated with
an increased in-hospital survival in NSTE-ACS patients with
concomitant DM. These results support the 2014 ACCF/AHA
guideline recommendations for an early invasive strategy in
diabetics, especially those with high-risk features (eg, NSTEMI
and cardiogenic shock).10 Meanwhile, the use of this strategy
in lower risk patients, such as those with UA, may not be
associated with improved survival.
The survival beneﬁt of an early invasive strategy in the
NSTE-ACS population remains a matter of ongoing debate.20–22
Whereas none of the landmark trials comparing an early
invasive with an initial conservative strategy illustrated a
statistically signiﬁcant reduction in mortality, these trials were
not statistically powered to answer that question.21–24 We
calculated the minimal sample size required by a randomized
trial to detect the difference in proportions illustrated in our
study and found that the sample size of almost 3500 patients
would be necessary to obtain the same results,25,26 which is
more than double the number of diabetic NSTE-ACS patients

Journal of the American Heart Association
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Table 2. Patient and Hospital Characteristics of Both the Unmatched and Propensity-Score–Matched Cohort of Patients
Unmatched Patients

Propensity-Score Matched

Variable

Early Invasive (%)

Initial Conservative (%)

Total number of patients

164 740 (100)

198 760 (100)

161 020 (98)

185 055 (93)

3720 (2)

P Value

Early Invasive (%)

Initial Conservative (%)

P Value*

21 681 (100)

21 681 (100)

<0.0001

21 130 (98)

20 247 (93)

<0.0001

13 705 (7)

<0.0001

550 (3)

1434 (7)

<0.0001

Primary diagnosis
NSTEMI†
UA

†

Patient demographics
Age, mean y (SD)

65 (12)

71 (13)

<0.0001

67 (11)

68 (13)

0.09

Female sex

64 130 (39)

91 945 (46)

<0.0001

9044 (42)

9176 (42)

0.20

<0.0001

Race

<0.0001*

White

109 040 (70)

128 515 (69)

15 063 (70)

14 983 (69)

Black

20 000 (13)

26 500 (14)

2768 (13)

3163 (15)

Hispanic

16 295 (10)

20 015 (11)

2227 (10)

2093 (10)

Asian or Pacific Islander

4400 (3)

5660 (3)

606 (3)

577 (3)

Other

6110 (4)

5655 (3)

868 (4)

710 (3)

Medicare

95 625 (58)

142 420 (72)

14 157 (65)

14 262 (66)

Medicaid

12 845 (8)

14 590 (7)

1477 (7)

1798 (8)

Private insurance

39 630 (24)

28 845 (14)

4327 (20)

3902 (18)

Uninsured

10 160 (6)

7390 (3)

1037 (5)

1075 (5)

Other

5110 (3)

4565 (2)

581 (3)

554 (3)

33 325 (20)

59 330 (30)

5279 (24)

5379 (25)

<0.0001

Primary expected payer

Weekend admission

<0.0001

0.02*

Downloaded from http://ahajournals.org by on February 27, 2019

<0.0001

Household income (median)

0.27
<0.0001*

0 to 25th percentile

53 420 (33)

66 370 (34)

7384 (34)

7280 (34)

26 to 50th percentile

43 660 (27)

51 265 (26)

5821 (27)

5668 (26)

51 to 75th percentile

36 995 (23)

43 555 (23)

4895 (23)

4921 (23)

76 to 100th percentile

27 175 (17)

32 760 (17)

3581 (17)

3812 (18)

Patient characteristics
Smoking

54 065 (33)

44 355 (22)

<0.0001

6067 (28)

5901 (27)

0.08

Dyslipidemia

125 075 (76)

131 195 (66)

<0.0001

15 786 (73)

15 666 (72)

0.20

Obesity

45 060 (27)

43 055 (21)

<0.0001

5449 (25)

5369 (25)

0.38

Known history of CAD

146 755 (89)

136 395 (69)

<0.0001

18 399 (85)

18 493 (85)

0.21

Family history of CAD

13 100 (8)

7365 (4)

<0.0001

1148 (5)

1115 (5)

0.48

Past MI

20 705 (13)

25 895 (13)

<0.0001

2922 (14)

3011 (14)

0.21

Past PCI

137 975 (84)

172 170 (87)

<0.0001

3519 (16)

3548 (16)

0.71

Past CABG

12 640 (8)

24 895 (13)

<0.0001

2178 (10)

2269 (11)

0.15

Past stroke or TIA

9150 (6)

13 390 (7)

<0.0001

1316 (6)

1321 (6)

0.92

Carotid artery disease

4080 (3)

4750 (2)

0.09

573 (3)

575 (3)

0.95

Peripheral vascular disease

25 335 (15)

36 090 (18)

<0.0001

3819 (18)

3817 (18)

0.98

Pulmonary circulation disease

145 (<1)

275 (<1)

<0.0001

21 (<1)

29 (<1)

0.26

Dementia

3000 (2)

15 350 (8)

<0.0001

562 (3)

508 (2)

0.10

Atrial fibrillation

22 725 (14)

39 970 (20)

<0.0001

3536 (16)

3578 (17)

0.59

Alcohol abuse

3525 (2)

3830 (2)

<0.0001

454 (2)

434 (2)

0.50

Deficiency anemia

32 325 (20)

55 310 (28)

<0.0001

5062 (23)

5101 (24)

0.66
Continued
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Table 2. Continued
Unmatched Patients
Variable

Early Invasive (%)

Propensity-Score Matched
Initial Conservative (%)

P Value

Early Invasive (%)

Initial Conservative (%)

P Value*

Collagen vascular disease

3505 (2)

4410 (2)

0.06

480 (2)

471 (2)

0.79

Chronic blood loss anemia

1295 (1)

2085 (1)

<0.0001

197 (1)

200 (1)

0.88

Congestive heart failure

690 (<1)

2005 (1)

<0.0001

124 (<1)

145 (<1)

0.20

Valvular disease

195 (<1)

615 (<1)

<0.0001

36 (<1)

47 (<1)

0.23

Chronic pulmonary disease

35 540 (22)

52 430 (26)

<0.0001

5252 (24)

5322 (25)

0.43

Coagulopathy

9480 (6)

11 610 (6)

0.27

1313 (6)

1280 (6)

0.50

Liver disease

2895 (2)

4385 (2)

<0.0001

420 (2)

416 (2)

0.89

Renal disease (chronic)

41 815 (25)

78 900 (40)

<0.0001

6967 (32)

7005 (32)

0.70

Electrolytes abnormalities

34 070 (21)

56 890 (29)

<0.0001

5170 (24)

5203 (24)

0.71

AIDS

120 (<1)

175 (<1)

0.12

16 (<1)

14 (<1)

0.72

Drug abuse

3050 (2)

3425 (2)

<0.0001

392 (2)

394 (2)

0.94

Depression

14 495 (9)

19 320 (10)

<0.0001

1971 (9)

2040 (9)

0.25

Hypertension

138 115 (84)

162 920 (82)

<0.0001

18 088 (83)

18 086 (83)

0.98

Hypothyroidism

19 215 (12)

29 180 (15)

<0.0001

2801 (13)

2819 (13)

0.80

Lymphoma

705 (<1)

1240 (0.6)

<0.0001

110 (<1)

114 (<1)

0.79

Metastatic cancer

625 (<1)

2050 (1)

<0.0001

114 (<1)

106 (<1)

0.59
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Solid tumor without metastasis

1720 (1)

3480 (2)

<0.0001

289 (1)

295 (1)

0.80

Other neurological disorder

7385 (5)

16 065 (8)

<0.0001

1142 (5)

1192 (6)

0.29

Paralysis

2735 (2)

5445 (3)

<0.0001

431 (2)

457 (2)

0.38

Psychoses

4040 (3)

6860 (4)

<0.0001

622 (3)

597 (3)

0.47

Peptic ulcer (nonbleeding)

35 (<1)

35 (<1)

0.43

4 (<1)

2 (<1)

0.41

Weight loss

3330 (2)

6725 (3)

<0.0001

542 (3)

518 (2)

0.46

Cardiogenic shock

6100 (4)

5220 (3)

<0.0001

678 (3)

654 (3)

0.50

Intracranial hemorrhage

150 (<1)

255 (<1)

<0.0001

21 (<1)

24 (<1)

0.66

Acute ischemic stroke

2315 (1)

3185 (2)

<0.0001

328 (2)

337 (2)

0.73

Gastrointestinal bleeding

2545 (2)

5530 (3)

<0.0001

433 (2)

455 (2)

0.46

159 585 (97)

59 810 (30)

<0.0001

10 415 (48)

3862 (18)

<0.0001

25 650 (16)

11 760 (6)

<0.0001

3037 (14)

1820 (8)

<0.0001

Invasive procedure
PCI†
†

CABG

Hospital characteristics
<0.0001

Hospital bed size

0.05

Small

13 150 (8)

26 530 (13)

2062 (10)

2203 (10)

Medium

40 040 (24)

54 740 (28)

5568 (26)

5553 (26)

Large

111 550 (68)

117 490 (59)

14 051 (65)

13 925 (64)

<0.0001

Hospital location
Urban teaching

92 320 (56)

91 430 (46)

0.14
11 133 (51)

11 532 (53)

Urban nonteaching

61 130 (37)

81 580 (41)

8811 (41)

8213 (38)

Rural

11 290 (7)

25 750 (13)

1737 (8)

1936 (9)

3320 (2.0)

9605 (4.8)

475 (2.2)

826 (3.8)

In-hospital mortality

<0.0001

<0.0001

All percentages are approximated to the nearest integer. AIDS indicates acquired immune deﬁciency syndrome; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease;
NSTEMI, non-ST-elevation myocardial infarction; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIA, transient ischemic attack; UA, unstable angina.
*Although P value is signiﬁcant the difference in % between both arms was <5% and thus deemed clinically nonsigniﬁcant.
†
Variables were not included in the propensity score matching.
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Figure 1. A cluster column graph comparing all outcomes of interest between an early invasive and an
initial conservative strategy. LOS, length of hospital stay; $, US dollars.
Both length of hospital stay and total hospital charges were derived from the propensity-matched cohort of
patients.
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included in all previous trials combined.9 Although our results
suggest an association between an early invasive strategy and
improved survival in diabetics with NSTE-ACS, this does not
establish causality, given the retrospective nature of the data;
thus, larger randomized, clinical trials powered for differentiation between short- and long-term mortality are necessary
to conﬁrm our ﬁndings.
Earlier meta-analyses of randomized trials have demonstrated a possible reduction in all-cause mortality following an
early invasive strategy, with a mean follow-up of 1.5 to
2 years after the initial event.20,22 However, subsequent
meta-analyses failed to replicate the same results.7,27 A metaanalysis of 9904 patients with NSTE-ACS from 9 randomized
trials investigated the beneﬁt of an early invasive strategy use
in diabetics (17% of the total population) compared to
nondiabetics.9 Although the study did not show any added
mortality beneﬁt with an early invasive strategy, it showed a
reduction in the rate of nonfatal MI.9
Interestingly, the beneﬁt of an early invasive strategy was
least evident in the subgroup of diabetics diagnosed primarily
with UA. This is consistent with previous evidence showing a
lack of beneﬁt of an early invasive strategy in low-risk NSTEACS patients with low troponin levels28 and supports
choosing an initial conservative strategy as a valid option in
this subset of patients. Another ﬁnding was the infrequent use
of an early invasive strategy in high-risk diabetic patients
admitted with NSTE-ACS and cardiogenic shock. Only, 54% of
the patients with cardiogenic shock underwent an early
DOI: 10.1161/JAHA.116.005369

invasive strategy, however, those patients were the ones who
beneﬁted the most from this strategy with the lowest odds of
in-hospital mortality compared with both conservatively
managed cardiogenic shock patients and noncardiogenic
shock patients managed by an early invasive strategy.
A signiﬁcant effect modiﬁcation inﬂuenced by the admission
day was evident, with less beneﬁt noted with an early invasive
strategy, if the patients were admitted during weekends
compared with weekdays (Pinteraction=0.02). Although the exact
reasons for such differences are not entirely clear, it may be
attributed to lack of a readily available catheterization staff
together with some human factors, such as sleep deprivation
and fatigue as observed in previous studies.29 Despite this, the
incidence of in-hospital mortality remained signiﬁcantly lower
with an early invasive strategy when compared with an initial
conservative strategy during the weekends (OR=0.71; 95% CI,
0.57–0.90; P<0.0001).
Even though a routine invasive strategy is recommended
for diabetics by major cardiovascular guideline committees,10,30 national registries worldwide have illustrated that
this strategy is still underutilized.6,10 Although the exact
explanation for this ﬁnding is unclear, our analysis indicates
that an early invasive strategy was used more frequently in
younger patients with less comorbidity at baseline, which is
usually not the case in most diabetics at the time of NSTEACS presentation.
Although the deﬁnition of timing for an early invasive
strategy (ie, within 48 hours) appears to be somewhat
Journal of the American Heart Association
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Figure 2. Forest plot representing subgroup analysis of in-hospital mortality according to various patient risk factors. ACS indicates acute
coronary syndrome; CABG, coronary artery bypass graft; CAD, coronary artery disease; CHF, congestive heart failure; MI, myocardial infarction;
NSTEMI, non-ST-elevation myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.

different in the current study compared with the ACC/AHA
guidelines, the same deﬁnition was adopted by the pivotal
trials comparing an early invasive strategy to an initial
conservative strategy, such as Treat Angina with Aggrastat
and Determine Cost of Therapy with an Invasive or Conservative Strategy—Thrombolysis in Myocardial Infarction 18
(TACTICS-TIMI 18; 4–48 hours),31 Invasive versus Conservative Treatment in Unstable Coronary Syndromes (ICTUS;
24–48 hours)21 and FRagmin and Fast Revascularisation
during InStability in Coronary artery disease II (FRISC II;
24–48 hours)23 trials. A procedure time of 24 hours was used
mainly to deﬁne an early invasive strategy in trials comparing
early with delayed invasive strategy.32 Thus, we preferred to
use the 48-hour deﬁnition of an early invasive strategy to be
consistent with previous trials comparing early invasive to
initial conservative strategies in NSTE-ACS patients.
To our knowledge, this study represents the largest
contemporary analysis comparing an early invasive with an
DOI: 10.1161/JAHA.116.005369

initial conservative strategy in diabetics with NSTE-ACS.
Although the NIS is an administrative database, the large
sample size of patients that allowed adequate power to
assess the main outcome of interest, together with the
diverse demographics of the included patients, large number
of patients’ and hospital characteristics, and various inhospital complications recorded, made this database an
excellent source to explore our question of interest. Multiple
similar trend and outcome studies have been published using
the NIS database, which validates its reliability in addressing
various practice issues.14,16,17,33 Despite these strengths, the
current study has some limitations.
First, although we adjusted for over 50 independent
variables in the propensity-matched analysis, the current
study is retrospective in nature and is subject to biases
attributed to unmeasured confounders. Second, the inherent
limitation of the NIS database, such as error in coding or
misdiagnosis, may have occurred; however, given the large
Journal of the American Heart Association
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Conclusions
In this large propensity score matched analysis, an early
invasive strategy was found to be associated with improved inhospital survival in diabetic patients, especially those with highrisk features, such as NSTEMI or cardiogenic shock. The use of
an early invasive strategy in diabetics with UA does not appear
to be beneﬁcial with a possible signal of harm, and thus an initial
conservative strategy may be a safer approach for these
patients. Our ﬁndings should be conﬁrmed with future trials that
are powered for detection of short- and long-term survival
beneﬁt of an early invasive strategy in diabetics with NSTE-ACS.
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revascularization history in our subgroup analysis as an
indirect assessment of patients with higher TIMI score, and
there was no evidence of effect modiﬁcation by either. Lack
of data regarding various types of medications administered
is an important limitation, given that the inability to administer certain medications (eg, anticoagulant and -platelet
agents) that are known to improve survival in NSTE-ACS,
because of the patients’ underlying comorbidities, might have
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Table S1. Patient and hospital characteristics of the post-hoc propensity matched cohort of patients
with lower match tolerance.
Variable (%)
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Number of patients
Patient demographics
Age, mean years (SD)
Female sex
Race
White
Black
Hispanic
Asian or Pacific Islander
Other
Primary expected payer
Medicare
Medicaid
Private insurance
Uninsured
Other
Weekend admission
Household income (median)
0-25th percentile
26-50th percentile
51-75th percentile
76-100th percentile
Patient characteristics
Smoking
Dyslipidemia
Obesity
Known history of CAD
Family history of CAD
Prior myocardial infarction
Prior PCI
Prior CABG
Prior stroke or TIA
Carotid artery disease
Peripheral vascular disease
Pulmonary circulation disease
Dementia
Atrial fibrillation
Alcohol abuse
Deficiency anemia
Collagen vascular disease
Chronic blood loss anemia
Congestive heart failure
Valvular disease
Chronic pulmonary disease
Coagulopathy

Propensity-score matched
Early invasive
Initial conservative
(%)
(%)
12,363(100)
12,367(100)

P-value

67.6(11)
5,122(41)

67.7(12)
5,271(41)

0.47
0.06
0.60

8,523(69)
1,652(14)
1,321(11)
350(3)
427(4)

8,543(69)
1,690(13)
1,284(10)
333(3)
419(3)

8,076(65)
960(8)
2,278(18)
662(5)
326(3)
3,064(25)

8,173(66)
985(8)
2,237(18)
586(5)
333(3)
3,026(25)

4,229(34)
3,248(26)
2,812(23)
2,074(17)

4,229(34)
3,239(26)
2,761(22)
2,138(17)

3,450(28)
8,919(72)

3,366(27)
8,905(72)

0.23
0.81

3,182(26)
10,365(84)
631(5)
1,668(14)
2,021(16)
1,251(10)
750(6)
325(3)
2,161(18)
15(<1)
353(3)
2,027(16)
259(2)
2,936(24)
254(2)
116(1)
68(<1)
15(<1)
3,013(24)
781(6)

3,103(25)
10,527(85)
624(5)
1,719(14)
2,034(16)
1,251(10)
730(6)
328(3)
2,231(18)
13(<1)
304(3)
2,034(16)
260(2)
2,976(24)
271(2)
126(1)
81(<1)
20(<1)
3,044(25)
711(6)

0.24
0.01
0.84
0.57
0.83
0.99
0.73
0.91
0.20
0.71
0.05
0.91
0.97
0.56
0.46
0.52
0.29
0.40
0.66
0.43

0.13

0.58
0.66

Liver disease
Renal disease (chronic)
Electrolytes abnormalities
AIDS
Drug abuse
Depression
Hypertension
Hypothyroidism
Lymphoma
Metastatic cancer
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Solid tumor without metastasis
Other neurological disorder
Paralysis
Psychoses
Peptic ulcer (non-bleeding)
Weight loss
Cardiogenic shock
Intra-cranial hemorrhage
Acute ischemic stroke
Gastrointestinal bleeding
Hospital characteristics
Hospital bed size
Small
Medium
Large
Hospital location
Urban teaching
Urban non-teaching
Rural
In-hospital mortality

236(2)
4,006(32)
3,006(24)
11(<1)
232(2)
1,156(9)
10,373(84)
1,579(13)
60(<1)
60(<1)

243(2)
4,044(33)
3,030(25)
9(<1)
225(2)
1,154(9)
10,290(83)
1,618(13)
67(<1)
74(<1)

0.75
0.62
0.73
0.65
0.74
0.96
0.14
0.47
0.54
0.23

165(1)
698(6)
236(2)
359(3)
1(<1)
317(3)
400(3)
9(<1)
194(2)
245(2)

148(1)
679(6)
250(2)
334(3)
1(<1)
327(3)
374(3)
15(<1)
182(2)
238(2)

0.33
0.59
0.52
0.33
1.00
0.69
0.34
0.22
0.53
0.75

1,161(9)
3,178(26)
8,024(65)

1,238(10)
3,176(26)
7,953(64)

0.25

0.21
6,309(49)
5,033(41)
1,021(8)
303(2.5)

6,453(50)
4,877(39)
1,037(8)
462(3.7)

<0.0001

All percentages are approximated to the nearest integer.
CAD= coronary artery disease, PCI= percutaneous coronary intervention, CABG= coronary artery bypass graft
surgery, TIA= transient ischemic attack, AIDS= acquired immune deficiency syndrome.

